ClinicalTrials.gg
CompletedNCT01727791Updated Jan 28, 2021Results posted

A Study Of Pregabalin (Lyrica) Drug Levels In Urine, Plasma And Breast Milk Of Healthy Lactating Women

A Phase 4 interventional study of pregabalin (Lyrica) in Healthy Lactating Women, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in Belgium. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This is a pharmacokinetic study to determine the safety and tolerability of pregabalin in healthy lactating women. The objectives are to determine whether pregabalin is secreted in breast milk and if so, to characterize pregabalin pharmacokinetics in breast milk. Other objectives are to estimate potential infant exposure to pregabalin if administered to lactating women and to characterize the safety and tolerability of pregabalin in lactating women.

Read the detailed description

Post approval commitment for the FDA

02

Conditions studied

  • Healthy Lactating Women

Browse trials for

Keywords

  • pharmacokinetic
  • pregabalin
  • lactation
03

In context

Breast Feeding

1,082 studies on the registry are indexed under Breast Feeding; 217 are open to participants now.

This study's enrollment of 10 is below the median of 100 across 845 interventional studies indexed under Breast Feeding.

Browse Breast Feeding studies →

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy lactating females between the ages of 18 and 45 years (inclusive) who are actively breast-feeding or expressing breast milk and are at least 12 weeks post partum.
  • Subjects must be willing to temporarily discontinue breast feeding their infants before the Day 1 evening dose through to 42 hours after the last dose

Exclusion criteria

Exclusion Criteria:

  • History of significant adverse reaction to pregabalin or gabapentin.
  • Subjects pregnant or unwilling or unable to comply with the Lifestyle guidelines presented in the protocol during the study period and through the follow-up visit.
  • Subjects with evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric (including post natal depression), neurologic or allergic disease (including drug allergies, but excluding untreated asymptomatic, seasonal allergies at time of dosing).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Non-randomized
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    open label

    Drug: pregabalin (Lyrica)

Interventions

  • Subjects will receive a single 150 mg dose of pregabalin in the evening of Day 1, a 150 mg dose of pregabalin in the morning and evening of Day 2 and a 150 mg dose in the morning of Day 3.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)

    Area under the plasma concentration-time profile from time 0 to tau (AUCtau), where tau was the dosing interval of 12 hours.

    Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3

  2. Maximum Observed Plasma Concentration (Cmax)

    Cmax was the peak concentration in plasma post Day 3 dose.

    Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Tmax was the time to peak concentration in plasma post Day 3 dose.

    Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3

  4. Plasma Half-Life (t1/2)

    Plasma decay half-life (t1/2) was the time for the plasma concentration to decrease by one-half. The t1/2 is based on the terminal elimination phase time points from this timeframe.

    Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3

  5. Average Plasma Concentration During the Dosing Interval (Cav)

    Average plasma concentration during the dosing interval (Cav) was calculated by dividing AUCtau (plasma) with tau, where tau was the dosing interval of 12 hours.

    Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3

  6. Minimum Observed Plasma Trough Concentration (Cmin)

    Cmin was the minimum observed plasma concentration of a drug after post Day 3 dose.

    Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3

  7. Apparent Oral Clearance (CL/F)

    Apparent oral clearance (CL/F) was calculated by dividing dose by the AUCtau, where tau was the dosing interval of 12 hours. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3

  8. Area Under the Curve From Time Zero to End of Dosing Interval for Breast Milk (AUCtau [Breast Milk])

    AUCtau (breast milk) was the area under the curve for breast milk, from time 0 to tau (AUCtau), where tau was the dosing interval of 12 hours.

    Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3

  9. Maximum Observed Concentration in Breast Milk (Cmax [Breast Milk])

    Cmax (breast milk) was the maximum observed concentration in breast milk post Day 3 dose.

    Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 32, 32 to 40 and 40 to 48 hours post-dose on Day 3

  10. Time to Reach Maximum Observed Breast Milk Concentration (Tmax [Breast Milk])

    Tmax (breast milk) was time of the maximum observed breast milk concentration Day 3 post-dose.

    Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 32, 32 to 40 and 40 to 48 hours post-dose on Day 3

  11. Terminal Half-Life for Breast Milk (t1/2 [Breast Milk])

    The terminal half-life for breast milk (t1/2 \[breast milk\]) was the time measured for breast milk concentration to decrease by one-half. For the first 5 participants enrolled under protocol amendment dated: 18 Sep 2012, breast milk was collected up to 24 hours after Day 3 dosing over the following time intervals: 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24 hours. Terminal half-life was determined over those points characterizing the elimination phase. For the remaining 5 participants, there were 3 additional collection intervals (24 to 32, 32 to 40, 40 to 48 hours) for characterizing the terminal elimination phase. The t1/2 (breast milk) is based on the terminal elimination phase time points from this timeframe.

    Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 32, 32 to 40 and 40 to 48 hours post-dose on Day 3

  12. Average Breast Milk Concentration During the Dosing Interval (Cav)

    Average breast milk concentration during the dosing interval (Cav) was calculated by dividing AUCtau (breast milk) with tau, where tau was the dosing interval of 12 hours.

    Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3

  13. Amount Excreted in Breast Milk Over the Dosing Interval Tau (Aetaubm)

    Aetaubm was the amount excreted in breast milk over the dosing interval tau (12 hours). It was calculated as the sum of (breast milk concentration \* sample volume) for each collection interval from 0 to 12 hours post-dose, where tau was the dosing interval of 12 hours. Sample volume was based on ratio of volume weight and density.

    Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3

  14. Percentage of Dose Excreted in Breast Milk During the Dosing Interval Tau (Aetaubm Percent)

    Percentage of dose excreted in breast milk during the dosing interval tau (Aetaubm percent) was calculated by using the formula: 100\*(Aetaubm \[sum of {breast milk concentration \* sample volume} for each collection interval from 0 to 12 hours post-dose\] divided by dose), where tau was the dosing interval of 12 hours.

    Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3

  15. Breast Milk Clearance (CLbm)

    Breast milk clearance (CLbm) was calculated by dividing Aetaubm (sum of \[breast milk concentration \* sample volume\] for each collection interval from 0 to 12 hours post-dose) by plasma AUCtau, where tau was the dosing interval of 12 hours.

    Time frame: Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3. Breast milk: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3

  16. Amount Recovered in Urine During the Dosing Interval Tau (Aetauurine)

    Aetauurine was the amount excreted in urine over the dosing interval tau (12 hours). It was calculated as the sum of (urine concentration \* sample volume) for each collection interval from 0 to 12 hours post-dose, where tau was the dosing interval of 12 hours. Here, sample volume was based on the ratio of volume weight and density.

    Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3

  17. Percent of Dose Recovered in Urine During the Dosing Interval Tau (Aetauurine Percent)

    Percent of dose recovered in urine during the dosing interval tau (Aetauurine percent) was calculated as 100\* (Aetau \[sum of {urine concentration \* sample volume} for each collection interval from 0 to 12 hours post-dose\] divided by the dose), where tau was the dosing interval of 12 hours.

    Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3

  18. Renal Clearance (CLr)

    Renal clearance (CLr) was the volume of plasma from which the drug was completely removed by the kidney in a given amount of time. It was calculated by dividing Aetauurine (sum of \[urine concentration \* sample volume\] for each collection interval from 0 to 12 hours post-dose) with the plasma AUCtau, where tau was the dosing interval of 12 hours.

    Time frame: Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3. Urine: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8 and 8 to 12 hours post-dose on Day 3

  19. Daily Amount of Pregabalin Excreted in Breast Milk (Ae24bm)

    Ae24bm was the daily amount of pregabalin excreted in breast milk. It was calculated by the formula: 2 \* Aetaubm (sum of \[breast milk concentration \* sample volume\] for each collection interval from 0 to 12 hours post-dose), where tau was the dosing interval of 12 hours.

    Time frame: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3

  20. Milk to Plasma Ratio for AUCtau (MPAUCtau)

    MPAUCtau was the ratio of AUCtau (breast milk) to AUCtau (plasma), where tau was the dosing interval of 12 hours.

    Time frame: Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3. Breast milk: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3

  21. Milk to Plasma Ratio for Maximum Observed Concentration (MPCmax)

    Milk to plasma ratio for maximum observed concentration (MPCmax) was calculated as the ratio of Cmax (breast milk) to Cmax (plasma).

    Time frame: Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3. Breast milk: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 32, 32 to 40 and 40 to 48 hours post-dose on Day 3

  22. Body Weight Normalized Infant Dose (BWNID)

    Body weight normalized infant dose (BWNID) of pregabalin was the dose that an infant received from breast-feeding and was calculated from the milk to plasma AUCtau ratio multiplied by the average maternal plasma pregabalin concentration (Cav) multiplied by the standardized milk consumption for an infant (150 milliliter/kilogram/day \[mL/kg/day\]), where tau was the dosing interval of 12 hours.

    Time frame: Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3. Breast milk: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3

  23. Body Weight Normalized Maternal Dose (BWNMD)

    Body weight normalized maternal dose (BWNMD) was calculated as the maternal dose in microgram per day (mcg/day) divided by maternal weight in kilogram (kg) at screening.

    Time frame: Pre-dose to 24 hours post-dose on Day 3

  24. Infant Dose Expressed as Percentage of Body Weight Normalized Maternal Dose (BWNIDPCM)

    Infant dose expressed as percentage of body weight normalized maternal dose (BWNIDPCM) was the relative infant dose (relative to maternal dose) calculated by the formula: 100 \* BWNID (Body Weight Normalized Infant Dose) / Body Weight Normalized Maternal Dose (BWNMD), where tau was the dosing interval of 12 hours.

    Time frame: Pre-dose to 24 hours post-dose on Day 3

Other outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.

    Time frame: Baseline up to 28 days after last dose of study drug

  2. Number of Participants With Laboratory Abnormalities

    The following parameters were analyzed for laboratory abnormalities: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume \[MCV\], mean corpuscular hemoglobin \[MCH\], mean corpuscular hemoglobin concentration \[MCHC\], platelets, white blood cell count, lymphocytes, total neutrophils, basophils, eosinophils, monocytes); liver function (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total protein, albumin); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, bicarbonate); clinical chemistry (glucose); urinalysis (urine pH, glucose, ketones, protein, urine blood/hemoglobin, nitrite).

    Time frame: Baseline up to 28 days after last dose of study drug

  3. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    The following parameters were analyzed for examination of vital signs: electrocardiogram (ECG), systolic and diastolic blood pressure, temperature, pulse rate, respiratory rate, radial pulse and body temperature.

    Time frame: Baseline up to 28 days after last dose of study drug

07

Results

Posted May 18, 2016

Participant flow

Eligible participants were healthy, lactating females between the ages of 18 and 45 years (inclusive) who were actively breastfeeding or expressing breast milk, who were at least 12 weeks post-partum and not currently pregnant.

Participant flow — Overall Study
MilestonePregabalin
Started10
Completed10
Not completed0

Outcome measures

PrimaryArea Under the Curve From Time Zero to End of Dosing Interval (AUCtau)

Area under the plasma concentration-time profile from time 0 to tau (AUCtau), where tau was the dosing interval of 12 hours.

Time frame:
Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3
Reported as:
Geometric mean · microgram*hour/milliliter (mcg*hr/mL)
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
microgram*hour/milliliter (mcg*hr/mL)Pregabalin
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)32.50 ± 24
PrimaryMaximum Observed Plasma Concentration (Cmax)

Cmax was the peak concentration in plasma post Day 3 dose.

Time frame:
Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3
Reported as:
Geometric mean · mcg/mL
Maximum Observed Plasma Concentration (Cmax)
mcg/mLPregabalin
Maximum Observed Plasma Concentration (Cmax)4.67 ± 18
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax)

Tmax was the time to peak concentration in plasma post Day 3 dose.

Time frame:
Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3
Reported as:
Median · hr
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrPregabalin
Time to Reach Maximum Observed Plasma Concentration (Tmax)2.01 (1.00 to 3.00)
PrimaryPlasma Half-Life (t1/2)

Plasma decay half-life (t1/2) was the time for the plasma concentration to decrease by one-half. The t1/2 is based on the terminal elimination phase time points from this timeframe.

Time frame:
Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3
Reported as:
Mean · hr
Plasma Half-Life (t1/2)
hrPregabalin
Plasma Half-Life (t1/2)5.624 ± 0.65656
PrimaryAverage Plasma Concentration During the Dosing Interval (Cav)

Average plasma concentration during the dosing interval (Cav) was calculated by dividing AUCtau (plasma) with tau, where tau was the dosing interval of 12 hours.

Time frame:
Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3
Reported as:
Geometric mean · mcg/mL
Average Plasma Concentration During the Dosing Interval (Cav)
mcg/mLPregabalin
Average Plasma Concentration During the Dosing Interval (Cav)2.709 ± 24
PrimaryMinimum Observed Plasma Trough Concentration (Cmin)

Cmin was the minimum observed plasma concentration of a drug after post Day 3 dose.

Time frame:
Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3
Reported as:
Geometric mean · mcg/mL
Minimum Observed Plasma Trough Concentration (Cmin)
mcg/mLPregabalin
Minimum Observed Plasma Trough Concentration (Cmin)1.246 ± 36
PrimaryApparent Oral Clearance (CL/F)

Apparent oral clearance (CL/F) was calculated by dividing dose by the AUCtau, where tau was the dosing interval of 12 hours. Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3
Reported as:
Geometric mean · mL/minute
Apparent Oral Clearance (CL/F)
mL/minutePregabalin
Apparent Oral Clearance (CL/F)76.90 ± 24
PrimaryArea Under the Curve From Time Zero to End of Dosing Interval for Breast Milk (AUCtau [Breast Milk])

AUCtau (breast milk) was the area under the curve for breast milk, from time 0 to tau (AUCtau), where tau was the dosing interval of 12 hours.

Time frame:
Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Reported as:
Geometric mean · mcg*hr/mL
Area Under the Curve From Time Zero to End of Dosing Interval for Breast Milk (AUCtau [Breast Milk])
mcg*hr/mLPregabalin
Area Under the Curve From Time Zero to End of Dosing Interval for Breast Milk (AUCtau [Breast Milk])24.64 ± 27
PrimaryMaximum Observed Concentration in Breast Milk (Cmax [Breast Milk])

Cmax (breast milk) was the maximum observed concentration in breast milk post Day 3 dose.

Time frame:
Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 32, 32 to 40 and 40 to 48 hours post-dose on Day 3
Reported as:
Geometric mean · mcg/mL
Maximum Observed Concentration in Breast Milk (Cmax [Breast Milk])
mcg/mLPregabalin
Maximum Observed Concentration in Breast Milk (Cmax [Breast Milk])2.474 ± 30
PrimaryTime to Reach Maximum Observed Breast Milk Concentration (Tmax [Breast Milk])

Tmax (breast milk) was time of the maximum observed breast milk concentration Day 3 post-dose.

Time frame:
Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 32, 32 to 40 and 40 to 48 hours post-dose on Day 3
Reported as:
Median · hr
Time to Reach Maximum Observed Breast Milk Concentration (Tmax [Breast Milk])
hrPregabalin
Time to Reach Maximum Observed Breast Milk Concentration (Tmax [Breast Milk])4.63 (3.08 to 6.16)
PrimaryTerminal Half-Life for Breast Milk (t1/2 [Breast Milk])

The terminal half-life for breast milk (t1/2 \[breast milk\]) was the time measured for breast milk concentration to decrease by one-half. For the first 5 participants enrolled under protocol amendment dated: 18 Sep 2012, breast milk was collected up to 24 hours after Day 3 dosing over the following time intervals: 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24 hours. Terminal half-life was determined over those points characterizing the elimination phase. For the remaining 5 participants, there were 3 additional collection intervals (24 to 32, 32 to 40, 40 to 48 hours) for characterizing the terminal elimination phase. The t1/2 (breast milk) is based on the terminal elimination phase time points from this timeframe.

Time frame:
Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 32, 32 to 40 and 40 to 48 hours post-dose on Day 3
Reported as:
Mean · hr
Terminal Half-Life for Breast Milk (t1/2 [Breast Milk])
hrPregabalin
Terminal Half-Life for Breast Milk (t1/2 [Breast Milk])8.117 ± 3.0871
PrimaryAverage Breast Milk Concentration During the Dosing Interval (Cav)

Average breast milk concentration during the dosing interval (Cav) was calculated by dividing AUCtau (breast milk) with tau, where tau was the dosing interval of 12 hours.

Time frame:
Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Reported as:
Mean · mcg/mL
Average Breast Milk Concentration During the Dosing Interval (Cav)
mcg/mLPregabalin
Average Breast Milk Concentration During the Dosing Interval (Cav)2.116 ± 27
PrimaryAmount Excreted in Breast Milk Over the Dosing Interval Tau (Aetaubm)

Aetaubm was the amount excreted in breast milk over the dosing interval tau (12 hours). It was calculated as the sum of (breast milk concentration \* sample volume) for each collection interval from 0 to 12 hours post-dose, where tau was the dosing interval of 12 hours. Sample volume was based on ratio of volume weight and density.

Time frame:
Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Reported as:
Geometric mean · mcg
Amount Excreted in Breast Milk Over the Dosing Interval Tau (Aetaubm)
mcgPregabalin
Amount Excreted in Breast Milk Over the Dosing Interval Tau (Aetaubm)286.9 ± 60
PrimaryPercentage of Dose Excreted in Breast Milk During the Dosing Interval Tau (Aetaubm Percent)

Percentage of dose excreted in breast milk during the dosing interval tau (Aetaubm percent) was calculated by using the formula: 100\*(Aetaubm \[sum of {breast milk concentration \* sample volume} for each collection interval from 0 to 12 hours post-dose\] divided by dose), where tau was the dosing interval of 12 hours.

Time frame:
Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Reported as:
Geometric mean · percentage of dose
Percentage of Dose Excreted in Breast Milk During the Dosing Interval Tau (Aetaubm Percent)
percentage of dosePregabalin
Percentage of Dose Excreted in Breast Milk During the Dosing Interval Tau (Aetaubm Percent)0.1913 ± 60
PrimaryBreast Milk Clearance (CLbm)

Breast milk clearance (CLbm) was calculated by dividing Aetaubm (sum of \[breast milk concentration \* sample volume\] for each collection interval from 0 to 12 hours post-dose) by plasma AUCtau, where tau was the dosing interval of 12 hours.

Time frame:
Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3. Breast milk: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Reported as:
Geometric mean · mL/min
Breast Milk Clearance (CLbm)
mL/minPregabalin
Breast Milk Clearance (CLbm)0.1473 ± 60
PrimaryAmount Recovered in Urine During the Dosing Interval Tau (Aetauurine)

Aetauurine was the amount excreted in urine over the dosing interval tau (12 hours). It was calculated as the sum of (urine concentration \* sample volume) for each collection interval from 0 to 12 hours post-dose, where tau was the dosing interval of 12 hours. Here, sample volume was based on the ratio of volume weight and density.

Time frame:
Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Reported as:
Geometric mean · mg
Amount Recovered in Urine During the Dosing Interval Tau (Aetauurine)
mgPregabalin
Amount Recovered in Urine During the Dosing Interval Tau (Aetauurine)133.1 ± 12
PrimaryPercent of Dose Recovered in Urine During the Dosing Interval Tau (Aetauurine Percent)

Percent of dose recovered in urine during the dosing interval tau (Aetauurine percent) was calculated as 100\* (Aetau \[sum of {urine concentration \* sample volume} for each collection interval from 0 to 12 hours post-dose\] divided by the dose), where tau was the dosing interval of 12 hours.

Time frame:
Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Reported as:
Geometric mean · percentage of dose
Percent of Dose Recovered in Urine During the Dosing Interval Tau (Aetauurine Percent)
percentage of dosePregabalin
Percent of Dose Recovered in Urine During the Dosing Interval Tau (Aetauurine Percent)88.6 ± 12
PrimaryRenal Clearance (CLr)

Renal clearance (CLr) was the volume of plasma from which the drug was completely removed by the kidney in a given amount of time. It was calculated by dividing Aetauurine (sum of \[urine concentration \* sample volume\] for each collection interval from 0 to 12 hours post-dose) with the plasma AUCtau, where tau was the dosing interval of 12 hours.

Time frame:
Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3. Urine: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8 and 8 to 12 hours post-dose on Day 3
Reported as:
Geometric mean · mL/min
Renal Clearance (CLr)
mL/minPregabalin
Renal Clearance (CLr)68.16 ± 24
PrimaryDaily Amount of Pregabalin Excreted in Breast Milk (Ae24bm)

Ae24bm was the daily amount of pregabalin excreted in breast milk. It was calculated by the formula: 2 \* Aetaubm (sum of \[breast milk concentration \* sample volume\] for each collection interval from 0 to 12 hours post-dose), where tau was the dosing interval of 12 hours.

Time frame:
Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Reported as:
Mean · mcg
Daily Amount of Pregabalin Excreted in Breast Milk (Ae24bm)
mcgPregabalin
Daily Amount of Pregabalin Excreted in Breast Milk (Ae24bm)664.6 ± 60
PrimaryMilk to Plasma Ratio for AUCtau (MPAUCtau)

MPAUCtau was the ratio of AUCtau (breast milk) to AUCtau (plasma), where tau was the dosing interval of 12 hours.

Time frame:
Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3. Breast milk: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Reported as:
Mean · ratio
Milk to Plasma Ratio for AUCtau (MPAUCtau)
ratioPregabalin
Milk to Plasma Ratio for AUCtau (MPAUCtau)0.769 (0.493 to 0.956)
PrimaryMilk to Plasma Ratio for Maximum Observed Concentration (MPCmax)

Milk to plasma ratio for maximum observed concentration (MPCmax) was calculated as the ratio of Cmax (breast milk) to Cmax (plasma).

Time frame:
Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12, 18, 24 hours post-dose on Day 3. Breast milk: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12, 12 to 24, 24 to 32, 32 to 40 and 40 to 48 hours post-dose on Day 3
Reported as:
Mean · ratio
Milk to Plasma Ratio for Maximum Observed Concentration (MPCmax)
ratioPregabalin
Milk to Plasma Ratio for Maximum Observed Concentration (MPCmax)0.5413 (0.335 to 0.755)
PrimaryBody Weight Normalized Infant Dose (BWNID)

Body weight normalized infant dose (BWNID) of pregabalin was the dose that an infant received from breast-feeding and was calculated from the milk to plasma AUCtau ratio multiplied by the average maternal plasma pregabalin concentration (Cav) multiplied by the standardized milk consumption for an infant (150 milliliter/kilogram/day \[mL/kg/day\]), where tau was the dosing interval of 12 hours.

Time frame:
Plasma: Pre-dose on Day 3; 0.5, 1, 2, 3, 4, 6, 10, 12 hours post-dose on Day 3. Breast milk: Pre-dose on Day 3; 0 to 2, 2 to 4, 4 to 8, 8 to 12 hours post-dose on Day 3
Reported as:
Mean · mcg/kg/day
Body Weight Normalized Infant Dose (BWNID)
mcg/kg/dayPregabalin
Body Weight Normalized Infant Dose (BWNID)317.3 ± 27
PrimaryBody Weight Normalized Maternal Dose (BWNMD)

Body weight normalized maternal dose (BWNMD) was calculated as the maternal dose in microgram per day (mcg/day) divided by maternal weight in kilogram (kg) at screening.

Time frame:
Pre-dose to 24 hours post-dose on Day 3
Reported as:
Mean · mcg/kg/day
Body Weight Normalized Maternal Dose (BWNMD)
mcg/kg/dayPregabalin
Body Weight Normalized Maternal Dose (BWNMD)4343.6 ± 27
PrimaryInfant Dose Expressed as Percentage of Body Weight Normalized Maternal Dose (BWNIDPCM)

Infant dose expressed as percentage of body weight normalized maternal dose (BWNIDPCM) was the relative infant dose (relative to maternal dose) calculated by the formula: 100 \* BWNID (Body Weight Normalized Infant Dose) / Body Weight Normalized Maternal Dose (BWNMD), where tau was the dosing interval of 12 hours.

Time frame:
Pre-dose to 24 hours post-dose on Day 3
Reported as:
Mean · percentage of dose
Infant Dose Expressed as Percentage of Body Weight Normalized Maternal Dose (BWNIDPCM)
percentage of dosePregabalin
Infant Dose Expressed as Percentage of Body Weight Normalized Maternal Dose (BWNIDPCM)7.341 ± 27
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and non-SAEs.

Time frame:
Baseline up to 28 days after last dose of study drug
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
participantsPregabalin
Number of Participants with AEs8
Number of Participants with SAEs0
Other pre-specifiedNumber of Participants With Laboratory Abnormalities

The following parameters were analyzed for laboratory abnormalities: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume \[MCV\], mean corpuscular hemoglobin \[MCH\], mean corpuscular hemoglobin concentration \[MCHC\], platelets, white blood cell count, lymphocytes, total neutrophils, basophils, eosinophils, monocytes); liver function (bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total protein, albumin); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, bicarbonate); clinical chemistry (glucose); urinalysis (urine pH, glucose, ketones, protein, urine blood/hemoglobin, nitrite).

Time frame:
Baseline up to 28 days after last dose of study drug
Reported as:
Number · participants
Number of Participants With Laboratory Abnormalities
participantsPregabalin
Number of Participants With Laboratory Abnormalities4
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

The following parameters were analyzed for examination of vital signs: electrocardiogram (ECG), systolic and diastolic blood pressure, temperature, pulse rate, respiratory rate, radial pulse and body temperature.

Time frame:
Baseline up to 28 days after last dose of study drug
Reported as:
Number · participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
participantsPregabalin
Number of Participants With Clinically Significant Change From Baseline in Vital Signs0

Adverse events

Collected over Baseline up to 28 days after last dose of study drug. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—0/10 (0%)8/10 (80%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPregabalin
DizzinessNervous system disorders6/10
HeadacheNervous system disorders2/10
DiarrhoeaGastrointestinal disorders1/10
Dry mouthGastrointestinal disorders1/10
NauseaGastrointestinal disorders1/10
VomitingGastrointestinal disorders1/10
FatigueGeneral disorders1/10
Back painMusculoskeletal and connective tissue disorders1/10
Muscular weaknessMusculoskeletal and connective tissue disorders1/10
Restless legs syndromeNervous system disorders1/10

Baseline characteristics

The baseline analysis population included participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Pregabalin
Mean31.7 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin
Female10
Male0
08

Study locations

1 site
  • Pfizer Clinical Research Unit
    Brussels, B-1070, Belgium
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2012
First posted
Nov 16, 2012
Start
Dec 2012
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
May 18, 2016
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01727791
Responsible party
Sponsor
First posted
Nov 16, 2012
Start date
Dec 2012
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
May 18, 2016
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion